Posts

GSK to license Hutchmed cancer drug for $110 million upfront

on

Otsuka’s VOYXACT Shows First IgAN Therapy to Stabilize Kidney Function Decline to Normal Physiologic Levels

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

on

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented at ESMO 2025

on

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

on

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso

on

J&J's Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection

on

J&J's Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

on